10x Genomics (TXG) cash on hand

Cash · fiscal 2025
$523.41M

10x Genomics (TXG) held cash of $523.41M at the end of fiscal 2025 (December 31, 2025). That is 33.0% higher than the $393.40M of fiscal 2024. Figures as of 18 Nov 2026, 04:44 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2025
$523.41M
Change on fiscal 2024
+33.0%
Highest on record
$523.41Mfiscal 2025
Lowest on record
$388.70Mfiscal 2023
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

10x Genomics cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $523.41M in fiscal 2025 and the lowest $388.70M in fiscal 2023.

History · 4 fiscal years

Cash by fiscal year

10x Genomics cash on hand, year by year

10x Genomics (TXG) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2025$523.41M 33.0% up
2024$393.40M 1.2% up
2023$388.70M 9.6% down
2022$429.98M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

Cash at health care companies of similar size

Cash of 10x Genomics and comparable companies
CompanyCashFiscal year
Twist Bioscience TWST$581.91M2026
Protagonist Therapeutics PTGX$567.36M2025
Krystal Biotech KRYS$827.79M2025
10x Genomics TXG$523.41M2025
HealthEquity HQY$318.93M2026
Corcept Therapeutics CORT$372.15M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TXG

10x Genomics, figure by figure

10x Genomics (TXG) overview: price, valuation and scorecardAll health care companies by market value

10x Genomics cash on hand: questions and answers

How much cash does 10x Genomics have?

10x Genomics (TXG) held cash of $523.41M at the end of fiscal 2025 (December 31, 2025). That is 33.0% higher than the $393.40M of fiscal 2024.

What are the highest and lowest cash figures on record for 10x Genomics?

Across the 4 fiscal years on record (2022–2025), the highest was $523.41M in fiscal 2025 and the lowest $388.70M in fiscal 2023.

How is 10x Genomics's cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “10x Genomics (TXG) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/TXG/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.